Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults with ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

Aquestive Therapeutics (AQST) announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine ...